Turning Science Into Products™

SynDevRx, Inc. (“SDX”) Cambridge, Massachusetts, established in 2007, is developing new and effective treatments for oncology and metabolic diseases including diabetes, obesity and fatty liver disease.

Our treatments are best-in-class MetAP2 inhibitors of the fumagillin drug class and were developed using our proprietary conjugation technology that improves efficacy and safety while reducing drug dose >10x the small molecule equivalent.

SDX has demonstrated exceptional activity and safety in preclinical proof-of-concept models for both oncology and obesity. Our polymer-drug conjugates provide a solution to the problem of off-target toxicities, addressing a primary cause of clinical trial failures for many small molecules.

Our technology increases a drug's therapeutic index by concentrating activity at the disease site.  It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile.

Our treatments target metabolic disesaes and cancer by inhibiting MetAP2 - an enzyme which independent research has shown to be key to proper metabolic functioning and tumor growth, proliferation and metastasis.  The technology keeps the active drug inert while in general circulation thereby greatly reducing toxicities associated with non-specific bio-distribution.

Our technology is available for partnering.